Neoadjuvant TRK inhibitors versus chemotherapy in advanced NTRK fusion-positive sarcomas: a real-world evidence analysis.

Although the difference did not reach statistical significance, the incidence in the chemotherapy group was as high as 33.3% (3/9), while no such events occurred in the targeted group.

also in 111,027 other papers